
Solid Biosciences (SLDB) Stock Forecast & Price Target
Solid Biosciences (SLDB) Analyst Ratings
Bulls say
Solid Biosciences is attractive because its SGT-003 DMD program combines a differentiated capsid, the unique R16/R17 nNOS feature, and a steroid-only prophylaxis regimen that has shown no drug-induced liver injury in 53 dosed patients, alongside consistent biomarker evidence across expression, CK, troponin, and LVEF. The company is also better positioned than before to navigate regulation, with FDA leadership viewed as more constructive and a randomized confirmatory trial already underway, which could support a favorable accelerated-approval discussion in late 4Q26. Beyond DMD, SGT-212, SGT-501, and SGT-601 add optionality, while the stock’s enterprise value of about $700m appears to underwrite limited credit for a platform that could address a large, still-untreated DMD population and broader cardiac and neuromuscular diseases.
Bears say
Solid Biosciences is viewed negatively because its core gene-therapy platform remains exposed to unresolved clinical, regulatory, and safety risks, including the possibility of immune-mediated toxicity, clinical holds, and failures to prove sustained efficacy. The company’s dependence on a small set of programs means a setback in DMD, FA, or CPVT could impair platform value materially, while competition and pricing pressure could compress any eventual commercial opportunity. Financially, the balance sheet appears limited for a development-stage biotech, with ~$236 million in cash, cash equivalents, investments, and available-for-sale securities as of September 30, 2025, leaving a meaningful likelihood that additional financing or partnerships will be needed.
This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Solid Biosciences (SLDB) Analyst Forecast & Price Prediction
Start investing in Solid Biosciences (SLDB)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Solid Biosciences (SLDB) Forecast
Solid Biosciences (SLDB) Analyst Forecast & Price Prediction
Start investing in Solid Biosciences (SLDB)
Order type
Buy in
Order amount
Est. shares
0 shares